文献速递母胎医学

基于cSMART的无创产前诊断用于β地中海贫血高危妊娠的回顾性研究

Noninvasive prenatal diagnosis for pregnancies at risk for β-thalassaemia: a retrospective study.
PubMed 文献 · BJOG · 2020-05-28

该回顾性研究纳入102对携带HBB致病变异的中国孕妇夫妇,孕期均接受传统侵入性产前诊断(IPD),随后用cSMART法对存档血浆DNA行无创产前诊断(NIPD)评估胎儿HBB基因型。与IPD结果相比,NIPD正确判读99/102例胎儿(97%),灵敏度100%(95%CI 88.06-100.00%),特异度97.26%(95%CI 90.45-99.67%)。研究表明cSMART-based NIPD有望作为IPD的替代方案。

要点

  • cSMART法NIPD对β地贫高危胎儿基因分型正确率97%(99/102)。
  • NIPD灵敏度100%(95%CI 88.06-100.00%),特异度97.26%(95%CI 90.45-99.67%)。
  • 3例不一致中2例假阳性,1例将杂合携带误判为正常纯合。

核心结论

  • 基于cSMART的β地中海贫血NIPD检测在携带HBB致病变异的孕妇夫妇中具有作为IPD替代方案的潜在临床实用性。

研究设计与样本

  • 回顾性研究,通过携带者筛查招募102对携带HBB致病变异的中国孕妇夫妇,孕期均按传统IPD管理,后对存档血浆DNA行NIPD回顾性评估。

主要发现

  • IPD检出29例患病纯合子或复合杂合子、54例杂合子、19例正常纯合子。
  • 与IPD相比,NIPD正确判读99/102例胎儿(97%)。
  • 3例不一致样本中2例为假阳性,另1例将杂合携带者误判为正常纯合子。
  • NIPD灵敏度100%(95%CI 88.06-100.00%),特异度97.26%(95%CI 90.45-99.67%)。

临床怎么用

  • 对携带HBB致病变异的高危夫妇,cSMART法NIPD可作为IPD的潜在替代选择,但需注意假阳性和杂合子误判风险。

局限性

  • 回顾性研究设计,样本为102对携带HBB致病变异的中国夫妇,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical feasibility of noninvasive prenatal diagnosis (NIPD) for β-thalassaemia using circulating single molecule amplification and re-sequencing technology (cSMART). DESIGN: Through carrier screening, 102 pregnant Chinese couples carrying pathogenic HBB gene variants were recruited to the study. Pregnancies were managed using traditional invasive prenatal diagnosis (IPD). Retrospectively, we evaluated the archived pregnancy plasma DNA by NIPD to evaluate the performance of our cSMART assay for fetal genotyping. SETTING: Chinese prenatal diagnostic centres specialising in thalassaemia testing. POPULATION: Chinese carrier couples at high genetic risk for β-thalassaemia. METHODS: Fetal cell sampling was performed by amniocentesis and HBB genotypes were determined by reverse dot blot. NIPD was performed by a newly designed HBB cSMART assay and fetal genotypes were called by measuring the allelic ratios in the maternal cell-free DNA. MAIN OUTCOME MEASURES: Concordance of HBB fetal genotyping between IPD and NIPD and the sensitivity and specificity of NIPD. RESULTS: Invasive prenatal diagnosis identified 29 affected homozygotes or compound heterozygotes, 54 heterozygotes and 19 normal homozygotes. Compared with IPD results, 99 of 102 fetuses (97%) were correctly genotyped by our NIPD assay. Two of three discordant samples were false positives and the other sample involved an incorrect call of a heterozygote carrier as a homozygote normal. Overall, the sensitivity and specificity of our NIPD assay was 100% (95% CI 88.06-100.00%) and 97.26% (95% CI 90.45-99.67%), respectively. CONCLUSIONS: This study demonstrates that our cSMART-based NIPD assay for β-thalassaemia has potential clinical utility as an alternative to IPD for pregnant HBB carrier couples. TWEETABLE ABSTRACT: A new noninvasive test for pregnancies at risk for β-thalassaemia.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Lv W, Linpeng S, Li Z, et al. Noninvasive prenatal diagnosis for pregnancies at risk for β-thalassaemia: a retrospective study. BJOG. 2020. PMID: 32363759. doi:10.1111/1471-0528.16295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。